ImmunoLogik GmbH
ImmunoLogik GmbH is dedicated to developing a new class of active substances to combat viral infections, including SARS-CoV-2 and HIV. The company focuses on innovative approaches such as broad-spectrum virostatics and DUB-inhibitors, with a strong emphasis on scientific research, patents, and collaborations with medical institutions. Their mission is to provide effective treatments for viral diseases and to protect their intellectual property through patents and strategic partnerships.
Industries
Nr. of Employees
small (1-50)
ImmunoLogik GmbH
Patents
Products
Lead DUB-inhibitor candidate for HIV
Small-molecule inhibitor targeting host deubiquitinating enzymes to inhibit HIV replication; reported to have patent protection in major jurisdictions.
Lead DUB-inhibitor candidate for SARS-CoV-2 and other coronaviruses
Host-targeted small-molecule DUB inhibitor reported to block replication of SARS-CoV-2 in vitro and developed with a strategy aimed at broad activity against coronaviruses.
Lead DUB-inhibitor candidate for HIV
Small-molecule inhibitor targeting host deubiquitinating enzymes to inhibit HIV replication; reported to have patent protection in major jurisdictions.
Lead DUB-inhibitor candidate for SARS-CoV-2 and other coronaviruses
Host-targeted small-molecule DUB inhibitor reported to block replication of SARS-CoV-2 in vitro and developed with a strategy aimed at broad activity against coronaviruses.
Services
Design and execution of preclinical programs to produce in vitro and in vivo efficacy, toxicity and mode-of-action data for therapeutic candidates.
Conduct of antiviral efficacy assays using virus isolates in BSL-2/3 facilities through academic partnerships.
Development of solubilizing excipients and formulation approaches to improve compound water solubility and administrability.
Support for filing and managing patent protection for small-molecule therapeutic candidates across jurisdictions.
Organisation and communication for crowd-based financing rounds and investor engagement.
Design and execution of preclinical programs to produce in vitro and in vivo efficacy, toxicity and mode-of-action data for therapeutic candidates.
Conduct of antiviral efficacy assays using virus isolates in BSL-2/3 facilities through academic partnerships.
Development of solubilizing excipients and formulation approaches to improve compound water solubility and administrability.
Support for filing and managing patent protection for small-molecule therapeutic candidates across jurisdictions.
Organisation and communication for crowd-based financing rounds and investor engagement.
Expertise Areas
- Antiviral drug discovery
- Host-targeted therapeutic development
- Deubiquitinase (DUB) biology and inhibitor development
- Preclinical virology and BSL-2/3 testing
Key Technologies
- Deubiquitinase (DUB) inhibition
- Host-targeted antiviral approaches
- In vitro virology assays
- BSL-2/3 laboratory operations
News & Updates
ImmunoLogik and the University Hospital Erlangen have decided to continue their successful cooperation and extended the cooperation contract until September 2023.
The European Patent Office in Munich has granted a patent for IML-106, a drug candidate for HIV and AIDS treatment, after a long review process.
ImmunoLogik was featured in a science documentary on 3sat, where Dr. Christian Setz discussed alternative funding methods for pharmaceutical development, including crowdfunding.
ImmunoLogik develops inhibitors of deubiquitinating enzymes (DUBs), which are important pharmacological targets for various diseases, including viral infections like HIV and SARS-CoV-2.
ImmunoLogik and the University Hospital Erlangen have decided to continue their successful cooperation and extended the cooperation contract until September 2023.
The European Patent Office in Munich has granted a patent for IML-106, a drug candidate for HIV and AIDS treatment, after a long review process.
ImmunoLogik was featured in a science documentary on 3sat, where Dr. Christian Setz discussed alternative funding methods for pharmaceutical development, including crowdfunding.
ImmunoLogik develops inhibitors of deubiquitinating enzymes (DUBs), which are important pharmacological targets for various diseases, including viral infections like HIV and SARS-CoV-2.